Annual CFO
-$56.03 M
+$54.75 M+49.42%
December 31, 2023
Summary
- As of February 7, 2025, CTMX annual cash flow from operations is -$56.03 million, with the most recent change of +$54.75 million (+49.42%) on December 31, 2023.
- During the last 3 years, CTMX annual CFO has fallen by -$61.29 million (-1165.51%).
- CTMX annual CFO is now -132.89% below its all-time high of $170.37 million, reached on December 31, 2017.
Performance
CTMX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$20.73 M
-$1.18 M-6.04%
September 30, 2024
Summary
- As of February 7, 2025, CTMX quarterly cash flow from operations is -$20.73 million, with the most recent change of -$1.18 million (-6.04%) on September 30, 2024.
- Over the past year, CTMX quarterly CFO has dropped by -$2.49 million (-13.63%).
- CTMX quarterly CFO is now -111.97% below its all-time high of $173.19 million, reached on June 30, 2017.
Performance
CTMX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$88.29 M
-$2.49 M-2.90%
September 30, 2024
Summary
- As of February 7, 2025, CTMX TTM cash flow from operations is -$88.29 million, with the most recent change of -$2.49 million (-2.90%) on September 30, 2024.
- Over the past year, CTMX TTM CFO has dropped by -$52.82 million (-148.94%).
- CTMX TTM CFO is now -150.49% below its all-time high of $174.85 million, reached on March 31, 2018.
Performance
CTMX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
CTMX Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +49.4% | -13.6% | -148.9% |
| 3 y3 years | -1165.5% | -13.6% | -148.9% |
| 5 y5 years | +25.8% | -13.6% | -148.9% |
CTMX Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +52.9% | -321.7% | +49.8% | -148.9% | +37.2% |
| 5 y | 5-year | -1165.5% | +60.1% | -121.3% | +58.3% | -452.4% | +41.6% |
| alltime | all time | -132.9% | +60.1% | -112.0% | +58.3% | -150.5% | +41.6% |
CytomX Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$20.73 M(+6.0%) | -$88.29 M(+2.9%) |
| Jun 2024 | - | -$19.55 M(-24.9%) | -$85.80 M(-6.2%) |
| Mar 2024 | - | -$26.05 M(+18.6%) | -$91.43 M(+63.2%) |
| Dec 2023 | -$56.03 M(-49.4%) | -$21.96 M(+20.4%) | -$56.03 M(+58.0%) |
| Sep 2023 | - | -$18.24 M(-27.5%) | -$35.47 M(-30.6%) |
| Jun 2023 | - | -$25.18 M(-369.3%) | -$51.07 M(-15.1%) |
| Mar 2023 | - | $9.35 M(-771.1%) | -$60.13 M(-45.7%) |
| Dec 2022 | -$110.79 M(-6.9%) | -$1.39 M(-95.9%) | -$110.79 M(-21.2%) |
| Sep 2022 | - | -$33.84 M(-1.1%) | -$140.59 M(+3.0%) |
| Jun 2022 | - | -$34.24 M(-17.1%) | -$136.44 M(+4.6%) |
| Mar 2022 | - | -$41.31 M(+32.4%) | -$130.40 M(+9.6%) |
| Dec 2021 | -$119.03 M(-2363.4%) | -$31.19 M(+5.0%) | -$119.03 M(+13.1%) |
| Sep 2021 | - | -$29.70 M(+5.3%) | -$105.27 M(+5.0%) |
| Jun 2021 | - | -$28.20 M(-5.8%) | -$100.24 M(-500.1%) |
| Mar 2021 | - | -$29.94 M(+71.8%) | $25.06 M(+376.4%) |
| Dec 2020 | $5.26 M(-103.7%) | -$17.43 M(-29.4%) | $5.26 M(-177.4%) |
| Sep 2020 | - | -$24.68 M(-125.4%) | -$6.79 M(+25.0%) |
| Jun 2020 | - | $97.10 M(-295.2%) | -$5.43 M(-96.4%) |
| Mar 2020 | - | -$49.74 M(+68.7%) | -$151.19 M(+7.6%) |
| Dec 2019 | -$140.48 M | -$29.48 M(+26.4%) | -$140.48 M(+0.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2019 | - | -$23.32 M(-52.1%) | -$139.74 M(+14.6%) |
| Jun 2019 | - | -$48.65 M(+24.7%) | -$121.97 M(+22.1%) |
| Mar 2019 | - | -$39.03 M(+35.8%) | -$99.94 M(+32.3%) |
| Dec 2018 | -$75.52 M(-144.3%) | -$28.74 M(+417.8%) | -$75.52 M(+204.8%) |
| Sep 2018 | - | -$5.55 M(-79.1%) | -$24.78 M(-0.7%) |
| Jun 2018 | - | -$26.62 M(+82.2%) | -$24.96 M(-114.3%) |
| Mar 2018 | - | -$14.61 M(-166.4%) | $174.85 M(+2.6%) |
| Dec 2017 | $170.37 M(-8484.5%) | $22.00 M(-483.4%) | $170.37 M(+13.4%) |
| Sep 2017 | - | -$5.74 M(-103.3%) | $150.31 M(+6.0%) |
| Jun 2017 | - | $173.19 M(-1007.4%) | $141.86 M(-1010.7%) |
| Mar 2017 | - | -$19.09 M(-1085.8%) | -$15.58 M(+666.6%) |
| Dec 2016 | -$2.03 M(-92.6%) | $1.94 M(-113.7%) | -$2.03 M(-83.3%) |
| Sep 2016 | - | -$14.18 M(-190.0%) | -$12.14 M(+112.1%) |
| Jun 2016 | - | $15.75 M(-384.4%) | -$5.72 M(-79.3%) |
| Mar 2016 | - | -$5.54 M(-32.2%) | -$27.59 M(+0.6%) |
| Dec 2015 | -$27.41 M(-186.2%) | -$8.17 M(+5.2%) | -$27.41 M(+42.4%) |
| Sep 2015 | - | -$7.77 M(+27.1%) | -$19.25 M(+67.6%) |
| Jun 2015 | - | -$6.11 M(+13.8%) | -$11.48 M(+113.8%) |
| Mar 2015 | - | -$5.37 M | -$5.37 M |
| Dec 2014 | $31.80 M(-497.1%) | - | - |
| Dec 2013 | -$8.01 M | - | - |
FAQ
- What is CytomX Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for CytomX Therapeutics?
- What is CytomX Therapeutics annual CFO year-on-year change?
- What is CytomX Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for CytomX Therapeutics?
- What is CytomX Therapeutics quarterly CFO year-on-year change?
- What is CytomX Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for CytomX Therapeutics?
- What is CytomX Therapeutics TTM CFO year-on-year change?
What is CytomX Therapeutics annual cash flow from operations?
The current annual CFO of CTMX is -$56.03 M
What is the all time high annual CFO for CytomX Therapeutics?
CytomX Therapeutics all-time high annual cash flow from operations is $170.37 M
What is CytomX Therapeutics annual CFO year-on-year change?
Over the past year, CTMX annual cash flow from operations has changed by +$54.75 M (+49.42%)
What is CytomX Therapeutics quarterly cash flow from operations?
The current quarterly CFO of CTMX is -$20.73 M
What is the all time high quarterly CFO for CytomX Therapeutics?
CytomX Therapeutics all-time high quarterly cash flow from operations is $173.19 M
What is CytomX Therapeutics quarterly CFO year-on-year change?
Over the past year, CTMX quarterly cash flow from operations has changed by -$2.49 M (-13.63%)
What is CytomX Therapeutics TTM cash flow from operations?
The current TTM CFO of CTMX is -$88.29 M
What is the all time high TTM CFO for CytomX Therapeutics?
CytomX Therapeutics all-time high TTM cash flow from operations is $174.85 M
What is CytomX Therapeutics TTM CFO year-on-year change?
Over the past year, CTMX TTM cash flow from operations has changed by -$52.82 M (-148.94%)